Metabolic phenotyping of diabetic nephropathy

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 5, 2013, Pages 566-569

  Makinen V P ^a,b,c   Kangas, A J ^b   Soininen, P ^b,d   Wurtz P ^b,e   Groop, P H ^c,f,g   Ala Korpela, M ^b,d,h,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^h OULU UNIVERSITY HOSPITAL   (Finland)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALBUMIN; APOLIPOPROTEIN; BIOLOGICAL MARKER; C PEPTIDE; CHOLESTEROL; CREATININE; CYSTATIN C; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OROSOMUCOID; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; SPHINGOMYELIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIETARY INTAKE; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTESTINE FUNCTION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; LIPID DIET; LIPOTOXICITY; LIVER FUNCTION; METABOLISM; METABOLOMICS; MORTALITY; MUSCLE FUNCTION; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PERIPHERAL VASCULAR DISEASE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SKELETAL MUSCLE;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; RISK ASSESSMENT;

EID: 84886720291     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.158     Document Type: Article

References (5)

1. Daneman, D. Type 1 diabetes. Lancet 367, 847-858 (2006).
2. Kettunen, J. et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44, 269-276 (2012).
3. Mäkinen, V.P. et al.; FinnDiane Study Group. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol. 4, 167 (2008).
4. Mäkinen, V.P. et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J. Proteome Res. 11, 1782-1790 (2012).
5. Mäkinen, V.P. et al.; Finnish Diabetic Nephropathy Study Group. Triglyceridecholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: The FinnDiane Study. J. Intern. Med. 383-395 (2013).